Personalized Medicine Approaches in Primary Biliary Cirrhosis Drugs
Primary Biliary Cirrhosis (PBC), also known as primary biliary cholangitis, is a chronic autoimmune liver disease characterized by gradual destruction of the bile ducts inside the liver. This leads to accumulation of bile, causing liver damage and ultimately cirrhosis or liver failure if not treated effectively. Over the past decade, advancements in primary biliary cirrhosis drugs have revolutionized management options, providing hope for improved patient outcomes. Understanding the current drug landscape, emerging therapies, and dynamics is essential for healthcare stakeholders, investors, and pharmaceutical companies engaged in this field.
The cornerstone of Primary Biliary Cirrhosis Drugs treatment has traditionally been ursodeoxycholic acid (UDCA), an oral bile acid that improves liver enzyme levels and delays disease progression. UDCA works by promoting bile flow and exerting cytoprotective effects on liver cells. Despite its widespread use, approximately 30-40% of patients show inadequate response to UDCA alone, necessitating alternative or adjunctive therapies.
Primary Biliary Cirrhosis Drugs - https://www.coherentmarketinsights.com/market-insight/primary-biliary-cirrhosis-drugs-market-1539
